Market Update (NASDAQ:REGN): EYLEA® (aflibercept) Injection Recommended for Approval for the Treatment of Visual Impairment Due to Macular Edema Secondary to Central or Branch Retinal Vein Occlusion in the European Union
January 23, 2015 at 07:32 AM EST
[PR Newswire] – TARRYTOWN, N.Y., Jan. 23, 2015 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that EYLEA ® (aflibercept) Injection has been recommended for approval by the European Committee … Read . . . → Read More: Market Update (NASDAQ:REGN): EYLEA® (aflibercept) Injection Recommended for Approval for the Treatment of Visual Impairment Due to Macular Edema Secondary to Central or Branch Retinal Vein Occlusion in the European Union Similar Articles: Market Update (NASDAQ:REGN): EYLEA® (aflibercept) Injection Accepted for Priority Review by FDA for Diabetic Retinopathy in Patients with Diabetic Macular Edema Stock Update (NASDAQ:REGN): EYLEA® (aflibercept) Injection Receives FDA Approval for Macular Edema Following Retinal Vein Occlusion (RVO) Market Update: Regeneron Pharmaceuticals Inc (NASDAQ:REGN) – EYLEA® (aflibercept) Injection Receives FDA Breakthrough Therapy Designation for Diabetic Retinopathy in Patients with Diabetic Macular Edema